Stock Events

Stock Events

Syndax Pharmaceuticals

$23.48

44

-$0.02-0.09% Friday 20:00

Statistics

Day High

23.96

Day Low

23.22

52W High

25.34

52W Low

11.22

Volume

849,863

Avg. Volume

1,171,980

Mkt Cap

2B

P/E Ratio

-100.69

Dividend Yield

-

Dividend

-

Earnings

8MayConfirmed

Q3 2022

Q4 2022

Q1 2023

Q2 2023

Q3 2023

Q4 2023

Q1 2024

-1

-0.86

-0.72

-0.58

Expected EPS

-0.98

Actual EPS

-0.85

People Also Follow

This list is based on the watchlists of people on Stock Events who follow SNDX. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

Merck & Co., Inc. competes in the oncology space with its range of cancer treatments, potentially overlapping with Syndax's focus on cancer therapeutics.

Bristol-Myers Squibb

Bristol-Myers Squibb Company offers a portfolio of cancer drugs, directly competing with Syndax Pharmaceuticals in the oncology market.

AstraZeneca PLC has a strong presence in developing cancer treatments, including therapies that may compete with Syndax's pipeline.

Pfizer Inc. has a broad range of oncology products that could compete with Syndax Pharmaceuticals' cancer therapies.

Gilead Sciences

Gilead Sciences, Inc. is involved in the development of oncology and hematology drugs, areas where Syndax is also aiming to make an impact.

Amgen Inc. competes in the biopharmaceutical space, focusing on innovative therapies that could rival Syndax's cancer treatment solutions.

Novartis AG has a diversified portfolio in oncology, potentially competing with Syndax Pharmaceuticals in multiple areas of cancer treatment.

Roche Holding AG, through its pharmaceuticals division, develops cancer drugs that could be in direct competition with Syndax's offerings.

Incyte Corporation focuses on the discovery, development, and commercialization of proprietary therapeutics, including cancer treatments that may compete with Syndax.

Exelixis, Inc. is focused on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers, directly competing with Syndax Pharmaceuticals.

Analyst Ratings

34.5$Average Price Target

The highest estimate is $42.

From 6 ratings within the last 6 months. This is not an investment recommendation.

Buy

83%

Hold

17%

Sell

0%

About

Health Technology

Biotechnology

Manufacturing

Pharmaceutical Preparation Manufacturing

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD). The company is also developing Entinostat. It also has collaborative research and development agreement with National Cancer Institute; a clinical trial agreement with Eastern Cooperative Oncology Group; and a license agreement with Kyowa Hakko Kirin Co., Ltd. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.Massachusetts.

Show more...

CEO

Briggs Morrison

Employees

184

Country

US

ISIN

US87164F1057

WKN

000A2AFL6

Listings